2024
Use of Muscle Relaxants After Surgery in Traditional Medicare Part D Enrollees
Bongiovanni T, Gan S, Finlayson E, Ross J, Harrison J, Boscardin J, Steinman M. Use of Muscle Relaxants After Surgery in Traditional Medicare Part D Enrollees. Drugs & Aging 2024, 41: 615-622. PMID: 38980644, PMCID: PMC11249446, DOI: 10.1007/s40266-024-01124-x.Peer-Reviewed Original ResearchConceptsMuscle relaxant prescriptionsOlder adultsSpine proceduresPain controlMuscle relaxationRisk of prolonged useProlonged useMedication-related problemsDecreased opioid useRates of prescribingMuscle relaxant useResultsThe study cohortPostoperative pain managementPrescribed to patientsYears of agePostoperative prescribingStudy DesignUsingNonopioid medicationsOpioid useOpioid prescribingMedicare Part DPostoperative periodMedicare Part D enrolleesRetrospective analysisPain management
2022
Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure
Faridi K, Dayoub E, Ross J, Dhruva S, Ahmad T, Desai N. Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure. Journal Of The American College Of Cardiology 2022, 79: 2516-2525. PMID: 35738713, DOI: 10.1016/j.jacc.2022.04.031.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsAngiotensin receptor neprilysin inhibitorQuadruple therapyOOP costsMedicare coveragePocket costsAngiotensin-converting enzyme inhibitorPrior authorizationAngiotensin receptor blockersQuadruple drug therapyCotransporter 2 inhibitorsMineralocorticoid receptor antagonistsReduced ejection fractionDrug plansReceptor blockersEjection fractionHeart failureDrug therapyReceptor antagonistPrescription drug plansMedicare patientsEnzyme inhibitorsTherapyRegimensMedication pricesAssociation Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology
Duarte-García A, Crowson CS, McCoy RG, Herrin J, Lam V, Putman MS, Ross JS, Matteson EL, Shah ND. Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology. Mayo Clinic Proceedings 2022, 97: 250-260. PMID: 35120693, PMCID: PMC9013005, DOI: 10.1016/j.mayocp.2021.08.026.Peer-Reviewed Original ResearchAssessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019
Zhou T, Liu P, Dhruva SS, Shah ND, Ramachandran R, Berg KM, Ross JS. Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019. JAMA Internal Medicine 2022, 182: 185-195. PMID: 34982097, PMCID: PMC8728660, DOI: 10.1001/jamainternmed.2021.7457.Peer-Reviewed Original ResearchMeSH KeywordsAgedAtrial FibrillationChronic DiseaseCross-Sectional StudiesDiabetes Mellitus, Type 2Drug CostsHealth ExpendituresHeart FailureHumansHypercholesterolemiaHypertensionMedicare Part CMedicare Part DMultiple Chronic ConditionsOsteoarthritisOsteoporosisPrescription DrugsPulmonary Disease, Chronic ObstructiveRetrospective StudiesUnited StatesConceptsCommon chronic diseasesGuideline-recommended medicationsGuideline-recommended managementPrescription drug plansCross-sectional studyChronic conditionsChronic diseasesPocket costsOlder adultsOutpatient medicationsMedicare prescription drug plansInitial treatmentMedicare Advantage plansRetrospective cross-sectional studyMultiple chronic conditionsMedicare Part D plansPart D plansSubstantial financial burdenAtrial fibrillationMAIN OUTCOMEExclusion criteriaMedicare beneficiariesAnnual outHypothetical patientsMedications
2020
Patterns of Opioid Prescribing among Medicare Advantage Beneficiaries with Pain and Cardiopulmonary Conditions
Feder SL, Canavan ME, Wang S, Kent EE, Kapo J, Presley CJ, Ross J, Davidoff AJ. Patterns of Opioid Prescribing among Medicare Advantage Beneficiaries with Pain and Cardiopulmonary Conditions. Journal Of Palliative Medicine 2020, 24: 195-204. PMID: 32673139, PMCID: PMC7840305, DOI: 10.1089/jpm.2020.0193.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalgesics, OpioidHumansMedicare Part CMedicare Part DPainPractice Patterns, Physicians'United StatesConceptsCardiopulmonary conditionsOpioid useMedicare Part D prescription claimsPatterns of opioidSevere pain interferenceUse of opioidsInitiation of opioidsMedicare Advantage beneficiariesNon-Hispanic blacksSelf-reported historyNon-Hispanic whitesOpioid prescribingSevere painNoncancer conditionsPain assessmentPain interferencePrescription claimsAdjusted proportionObservational studyPainPatientsOpioidsLogistic regressionOne-yearCancerProstaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017
Bartlett VL, Liu P, Dhruva SS, Shah ND, Bollinger KE, Ross JS. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017. Journal Of Managed Care & Specialty Pharmacy 2020, 26: 10.18553/jmcp.2020.26.4.562. PMID: 32223594, PMCID: PMC10391193, DOI: 10.18553/jmcp.2020.26.4.562.Peer-Reviewed Original ResearchMedicare beneficiaries' out-of-pocket costs for commonly used generic drugs, 2009-2017.
Liu P, Dhruva SS, Shah ND, Ross JS. Medicare beneficiaries' out-of-pocket costs for commonly used generic drugs, 2009-2017. The American Journal Of Managed Care 2020, 26: 112-117. PMID: 32181626, DOI: 10.37765/ajmc.2020.42635.Peer-Reviewed Original ResearchConceptsPrescription drug plansPocket costsMedicare prescription drug plansGeneric drugsDrug price transparencyCash pricesPrice transparencyPocket expenditureDiscount programDrug plansDrug discount programsMedicare beneficiariesGeneric drug discount programsBeneficiariesCostGeneric drug prescriptionPricesDrug listGeneric medications
2019
Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics
Vijay A, Gupta R, Liu P, Dhruva SS, Shah ND, Ross JS. Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics. Journal Of General Internal Medicine 2019, 35: 1928-1930. PMID: 31625043, PMCID: PMC7280368, DOI: 10.1007/s11606-019-05432-6.Peer-Reviewed Original ResearchMedicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors.
Egilman AC, Zhang AD, Wallach JD, Ross JS. Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors. Annals Of Internal Medicine 2019, 171: 521-523. PMID: 31404926, DOI: 10.7326/m19-1085.Peer-Reviewed Original ResearchMedicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies
Egilman AC, Wallach JD, Dhruva SS, Gonsalves GS, Ross JS. Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies. Journal Of General Internal Medicine 2019, 34: 2319-2321. PMID: 31313117, PMCID: PMC6848610, DOI: 10.1007/s11606-019-05149-6.Peer-Reviewed Original ResearchAssociation of Pharmaceutical Manufacturer Payments to Physicians and Prescribing Dosage of Opioids
Fleischman W, Agrawal S, Gross CP, Ross JS. Association of Pharmaceutical Manufacturer Payments to Physicians and Prescribing Dosage of Opioids. Journal Of General Internal Medicine 2019, 34: 1074-1076. PMID: 31011967, PMCID: PMC6614247, DOI: 10.1007/s11606-019-04897-9.Peer-Reviewed Original ResearchGeneric and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016
Ross JS, Rohde S, Sangaralingham L, Brito JP, Choi L, Dutcher SK, Graham DJ, Jenkins MR, Lipska KJ, Mendoza M, Qiang Y, Wang Z, Wu Y, Yao X, Shah ND. Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016. The Journal Of Clinical Endocrinology & Metabolism 2019, 104: 2305-2314. PMID: 30690529, DOI: 10.1210/jc.2018-02197.Peer-Reviewed Original ResearchConceptsBrand-name useDrug useMedicare AdvantageThyroid hormone replacement therapyLarge administrative claims databaseBeneficiary populationAdministrative claims databaseHormone replacement therapyCertain patient characteristicsMedicare Part DPrescriber specialtyPatient characteristicsPrescriber characteristicsClaims databaseReplacement therapyGeneric levothyroxineWhite raceHealth plansOlder adultsHormone drugsInsurance coverageProduct useLevothyroxineNational dataPart DMedicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013 to 2017
Vijay A, Ross JS, Shah ND, Jeffery MM, Dhruva SS. Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013 to 2017. Journal Of General Internal Medicine 2019, 34: 518-520. PMID: 30623386, PMCID: PMC6445908, DOI: 10.1007/s11606-018-4752-8.Peer-Reviewed Original Research
2018
Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval
Shaw DL, Dhruva SS, Ross JS. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval. Journal Of Managed Care & Specialty Pharmacy 2018, 24: 10.18553/jmcp.2018.24.12.1230. PMID: 30479199, PMCID: PMC10397592, DOI: 10.18553/jmcp.2018.24.12.1230.Peer-Reviewed Original ResearchConceptsNovel therapeutic agentsPrescription drug plansOrphan drug statusFDA approvalYear of approvalTherapeutic agentsNovel therapeuticsPrior authorizationNovel therapiesPriority reviewStep therapyMedicare prescription drug plansDrug plansDrug coverageNational InstituteDrug statusPart D prescription drug benefitMedicaid ServicesDrug characteristicsTherapeutic areasCross-sectional studyDrug benefit coverageHealth insurance payerBlue Cross Blue Shield AssociationPrescription drug benefitMedicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015
Egilman AC, Wallach JD, Ross JS, Dhruva SS. Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015. JAMA Internal Medicine 2018, 178: 567-569. PMID: 29340562, PMCID: PMC5876838, DOI: 10.1001/jamainternmed.2017.8016.Peer-Reviewed Original Research
2017
Medicare Formulary Coverage Restrictions for Prescription Opioids, 2006 to 2015.
Samuels EA, Ross JS, Dhruva SS. Medicare Formulary Coverage Restrictions for Prescription Opioids, 2006 to 2015. Annals Of Internal Medicine 2017, 167: 895-896. PMID: 29052693, DOI: 10.7326/m17-1823.Peer-Reviewed Original ResearchOpioid Prescribing for Opioid-Naive Patients in Emergency Departments and Other Settings: Characteristics of Prescriptions and Association With Long-Term Use
Jeffery MM, Hooten WM, Hess EP, Meara ER, Ross JS, Henk HJ, Borgundvaag B, Shah ND, Bellolio MF. Opioid Prescribing for Opioid-Naive Patients in Emergency Departments and Other Settings: Characteristics of Prescriptions and Association With Long-Term Use. Annals Of Emergency Medicine 2017, 71: 326-336.e19. PMID: 28967517, PMCID: PMC6295192, DOI: 10.1016/j.annemergmed.2017.08.042.Peer-Reviewed Original ResearchConceptsLong-term opioid useNon-ED settingsOpioid-naive patientsLong-term useOpioid prescriptionsOpioid useCharacteristics of prescriptionsPrescription opioid useLow daily dosesAdministrative claims dataRate of progressionDisabled Medicare beneficiariesMedicare Advantage beneficiariesED prescriptionGuideline concordancePatients 56Patients 58Opioid prescribingCDC guidelinesPrevention guidelinesDaily dosesEmergency departmentCDC recommendationsDays' supplyInclusion criteria
2016
Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study
Fleischman W, Agrawal S, King M, Venkatesh AK, Krumholz HM, McKee D, Brown D, Ross JS. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. The BMJ 2016, 354: i4189. PMID: 27540015, PMCID: PMC4989280, DOI: 10.1136/bmj.i4189.Peer-Reviewed Original ResearchConceptsHospital referral regionsOral anticoagulantsReferral regionsDiabetes drugsDrug classesGreater prescribingMedicare Part D beneficiariesAdditional daysPart D beneficiariesMedicare Part D prescriptionsCross-sectional analysisSectional ecological studyMedicare Part DPart D prescriptionsManufacturers of pharmaceuticalsPrescribingAnticoagulantsPhysiciansDrugsPart DEducational materialsSectional analysisStudy limitationsConsulting feesAssociation